Research programme: G protein-coupled receptor targeting therapies- MapLight Therapeutics/SandboxAQ
Latest Information Update: 16 Jan 2026
At a glance
- Originator MapLight Therapeutics; SandboxAQ
- Class
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research CNS disorders